Suppr超能文献

免疫抑制疗法对肾移植后CD4+CD25+ T细胞发育的影响。

The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation.

作者信息

Korczak-Kowalska G, Wierzbicki P, Bocian K, Klosowska D, Niemczyk M, Wyzgal J, Korecka A, Durlik M, Chmura A, Paczek L, Górski A

机构信息

Transplantation Institute, Medical University of Warsaw, Warsaw, Poland.

出版信息

Transplant Proc. 2007 Nov;39(9):2721-3. doi: 10.1016/j.transproceed.2007.09.015.

Abstract

A growing number of studies suggest that CD4(+)CD25(+) T regulatory (Treg) cells play a significant role to downregulate the immune response to alloantigens. In this study, we investigated the possible influence of immunosuppressive therapy, including cyclosporine (CsA) or rapamycin (sirolimus), on the level of CD4(+)CD25(+), CD4(+)CD25(+)FOXP3(+), and CD4(+)CD25(+)CTLA-4(+) T cells in the peripheral blood of renal allograft recipients. The study was performed on renal allograft recipients who displayed uneventful stable courses (RAR-S; n = 15) versus biopsy-proven chronic rejection (RAR-CH; n = 12). The patients were divided based on the immunosuppressive protocol: group 1 (prednisone+CsA+Aza) and group II (prednisone+sirolimus). The control group consisted of 10 healthy blood donors. We examined the expression of CD4, CD25, CTLA-4, and Foxp3 in peripheral blood T cells. Flow cytometry was performed with a FACSCalibur (BD Biosciences) instrument with data analyzed using Cell Quest software. The percentage of CD4(+)CD25(+)Foxp3(+) T cells in rapamycin (sirolimus) treated patients did not differ from that observed in healthy individuals, but was significantly higher compared with CsA-treated patients. CsA therapy resulted in a reduction in the percentage of CD4(+)CD25(+)CTLA-4(+) and CD4(+)CD25(+)Foxp3(+) regulatory T cells after renal transplantation in both groups (RAR-S and RAR-CH) compared with patients treated with rapamycin or to healthy donors. The type of immunosuppressive therapy (with or without calcineurin inhibitors) may have an important role in tolerance induction and graft function.

摘要

越来越多的研究表明,CD4(+)CD25(+)调节性T(Treg)细胞在下调对同种异体抗原的免疫反应中发挥重要作用。在本研究中,我们调查了免疫抑制治疗,包括环孢素(CsA)或雷帕霉素(西罗莫司),对肾移植受者外周血中CD4(+)CD25(+)、CD4(+)CD25(+)FOXP3(+)和CD4(+)CD25(+)CTLA-4(+) T细胞水平的可能影响。该研究针对肾移植受者进行,这些受者呈现出平稳稳定病程(RAR-S;n = 15)与经活检证实的慢性排斥反应(RAR-CH;n = 12)。患者根据免疫抑制方案进行分组:第1组(泼尼松+CsA+硫唑嘌呤)和第II组(泼尼松+西罗莫司)。对照组由10名健康献血者组成。我们检测了外周血T细胞中CD4、CD25、CTLA-4和Foxp3的表达。使用FACSCalibur(BD生物科学公司)仪器进行流式细胞术检测,并使用Cell Quest软件分析数据。雷帕霉素(西罗莫司)治疗的患者中CD4(+)CD25(+)Foxp3(+) T细胞的百分比与健康个体中观察到的百分比无差异,但与CsA治疗的患者相比显著更高。与接受雷帕霉素治疗的患者或健康供体相比,CsA治疗导致两组(RAR-S和RAR-CH)肾移植后CD4(+)CD25(+)CTLA-4(+)和CD4(+)CD25(+)Foxp3(+)调节性T细胞的百分比降低。免疫抑制治疗的类型(有无钙调神经磷酸酶抑制剂)可能在诱导耐受和移植物功能方面发挥重要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验